Novo-Nordisk (NVO)

He strongly disagrees with some analysts who say that the new weight-loss drugs won't move the needles of their company stocks. He expects huge demand for these drugs to battle diabetes, which would prevent many other diseases. He sees a lot of runway ahead for LLY and Novo Nordisk.

Good chart which is indicating momentum. Would recommend buying. 

It has had positive momentum but don't chase it. Two of its drugs are leaders in the space but we don't know the long term effects of these drugs. There are competing products being developed in the weight loss space.

Recent drug releases have been good for share price appreciation. Currently valued highly. Would wait for share price to fall before investing. Not a good time to buy. 

Headquartered in Denmark it is the leading global health care company with $32 billion in revenue expected in 2023 and estimates keep growing. It was recently crowned as Europe's most valuable company by market cap. It is the clear leader in diabetes care and obesity drug treatments and produces 50% of the world's insulin. Expected sales growth is 38% this year with operating profit growth of 46%. EPS growth is 25% going forward. 
Buy 4  Hold 1  Sell 1

Is one of the biggest producers of insulin. Also, now have a hit drug to treat obesity. It's no secret that Western countries have obesity problems. However, a lot of promise has been built in the valuation, based on this drug.

All such drug stocks are going down (oversold) due to inventory worries. But he likes this now.

They stumbled into the hit drug, Ozempic to treat obesity. Nobody knows the long-term effect of this drug yet, but sales are through the roof. NOVO now faces a lot of competition in weight-loss drugs. If you've made a big profit, take profits. 

Diabetes is not going away. Obesity has made its latest drug popular. Have to ask what are the side effects? Trading at 34-35x forward PE, with a 25%+ growth rate. PEG of 1.6x is not cheap, but not expensive. Overbought. He'd like to see it at the 50- or 200-day MA, around $170-175.

Both companies are leaders in the diabetes market which is one of the fastest growing areas. Although Eli Lilly is more well rounded he has owned Novo for many years. They are both in a good spot in developing drugs for Obesity - the question is will the insurance companies cover these drugs since Obesity is not a disease.

Benefitting from weight-loss drug, which will drive the stock for a long time. A massive market. It's gone up a lot, so you'll probably see a pullback. Insurance companies should love the health benefits and eventually cover the cost.

Are in the news with a new drug. He's owned this for nearly 20 years. They continue to grow free cash flow. Are adept at producing insulin, which is seeing growing demand due to global obesity. They have invested heavily in R&D, which yielded this new weight-loss drug which is doing well.

Good entry point, as it's pulled back from its high. Obesity causes Type 2 diabetes, the fastest-growing disease in NA. Globally, it's also becoming a problem. There's competition, but the potential is massive. Owning here makes sense.

Traditionally, insulin. Now into weight loss, big home run, stock has charged ahead. Up 40%. Only one approved by the FDA, the leader. Stock won't go down as long as sales keep up. Market is massive. See his Top Picks.

Has owned this for 20 years. They specialize in diabetes meds. They now have developed a weight-loss drug; shares have surged a lot in the past year given huge demand. NOVO can invest their cash flow into more R&D of drugs.